Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright

Key Points

• HC Wainwright cut Vera Therapeutics’ price target from $125 to $90 but maintained a “buy” rating, implying roughly 197% upside from the stock’s $30.29 price.
• Analyst sentiment remains broadly positive, with an average “Moderate Buy” rating and consensus price target of $81.15, despite one hold and one sell rating.
• Vera reported a quarterly loss of $1.52 per share, slightly better than the expected $1.56 loss. CEO Marshall Fordyce also sold 46,250 shares under a pre-arranged trading plan, reducing his stake by 23.33%.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) had its target price dropped by stock analysts at HC Wainwright from $125.00 to $90.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target indicates a potential upside of 197.13% from the company's current price.

Several other equities research analysts also recently issued reports on the stock. TD Cowen increased their price objective on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Jefferies Financial Group restated a "buy" rating and set a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Guggenheim upped their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a report on Wednesday, July 8th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $81.15.

Vera Therapeutics Stock Down 4.1%

VERA opened at $30.29 on Wednesday. Vera Therapeutics has a 12 month low of $19.93 and a 12 month high of $56.05. The business has a 50-day moving average of $36.51 and a two-hundred day moving average of $38.82. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -5.17 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.56) by $0.04. During the same period last year, the business earned ($1.20) EPS. On average, research analysts expect that Vera Therapeutics will post -6.37 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 46,250 shares of the business's stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares of the company's stock, valued at $6,429,346.20. This represents a 23.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company's stock worth $753,000 after buying an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock worth $2,354,000 after acquiring an additional 17,907 shares during the period. Jane Street Group LLC lifted its position in Vera Therapeutics by 297.1% in the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock valued at $999,000 after purchasing an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. grew its position in Vera Therapeutics by 550.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company's stock worth $7,316,000 after purchasing an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company's stock valued at $1,188,000 after buying an additional 825 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source